Docetaxel-associated epiphora

Pharmacotherapy

Volumn 26, Issue 6 I, 2006, Pages 853-867

  Kintzel, Polly E ^a   Michaud, Laura B ^b   Lange, Marianne K ^a  

^a SPECTRUM HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Docetaxel; Epiphora; Lacrimation; Weekly docetaxel administration

Indexed keywords

ARSENIC TRIOXIDE; ARTIFICIAL TEAR; CAPECITABINE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PENTOSTATIN; PREDNISONE; SODIUM CHLORIDE; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; DACRYOCYSTORHINOSTOMY; DAILY LIFE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; EYE IRRITATION; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; NEUTROPENIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SILASTIC TUBE; SOLID TUMOR; SYMPTOM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; LACRIMAL APPARATUS; LACRIMAL DUCT OBSTRUCTION; MALE; TAXOIDS;

EID: 33744471917     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.6.853     Document Type: Review

References (131)

1. Aventis Pharmaceuticals, Inc. Taxotere (docetaxel injection concentrate) package insert. Bridge-water, NJ; 2004.
2. Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-9.
3. Agelaki S, Veslemes M, Syrigos K, et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004;43:329-33.
4. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994;70:380-3.
5. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000;36:1016-25.
6. Kavanagh JJ, Kudelka AP, Gonzalez de Leon C, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-43.
7. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.
8. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15:1853-7.
9. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54.
10. Fossella F, Pereira JR, van Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-24.
11. Nabholtz JM, Senn HJ, Bezwoda D, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 1999;17:1413-24.
12. Frasci G, Comella P, Thomas R, et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients: a phase I study Cancer Chemother Pharmacol 2004;53:25-32.
13. Gómez-Bernal A, Cruz JJ, Garcia-Palomo A, et al. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer. Am J Clin Oncol 2003;26:127-31.
14. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:1346-50.
15. Sakai H, Yoneda S, Kobayashi K, et al. Phase II study of biweekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 2004;43:195-201.
16. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-19.
17. Esteban E, Gonzalez de Sande L, Fernández Y, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003;14:1640-7.
18. Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel therapy in breast cancer: evaluation of response and toxicity. Breast Cancer 2003;10:10-14.
19. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl cancer research network phase II trial. J Clin Oncol 2001;19:3500-5.
20. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer: a phase I/II dose escalation trial. Eur J Cancer 1998;34:838-44.
21. Stemmler HJ, Gutshow K, Sommer H, et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001;12:1393-8.
22. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic cancer. Ann Oncol 2002;13:286-92.
23. Kouroussi Ch, Agelaki S, Mavroudis D, et al. A dose-escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2000;46:488-92.
24. Zimatore M, Danova M, Vassallo E, et al. Weekly taxanes in metastatic breast cancer (review). Oncol Rep 2002;9:1047-52.
25. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long term administration. Ann Oncol 1999;10:701-6.
26. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004;95:624-31.
27. Ganjoo KN, Gordon MS, Sandler AB, et al. A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier oncology group study. Oncol 2002;62:299-304.
28. Inoue A, Kunitoh H, Mori K, Nukiwa T, Fukuoka M, Saijo N. Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. Lung Cancer 2002;38:205-9.
29. Kojima T, Shimazui T, Onozawa M, et al. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. Jpn J Clin Oncol 2004;34:137-41.
30. Mekhail T, Hutson TE, Elson P, et al. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer 2003;97:170-8.
31. Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K. Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy 2004;50:289-96.
32. Ohe Y, Niho S, Kakinuma R, et al. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 2001;31:100-6.
33. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005;16:1133-9.
34. Ramanathan RK, Ramalingam S, Egorin MJ, et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005;55:354-60.
35. Ramos M, González-Ageitos A, Amenedo M, et al. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 2003;15:192-7.
36. Rein DT, Kurbacher CM, Breidenbach M, et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 2002;87:98-103.
37. Wirth LJ, Lucca J, Ostler P, et al. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase 1 study. Clin Cancer Res 2003;9:1698-704.
38. Kuroi K, Bando H, Sah S, Toi M. Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 2003;10:1479-84.
39. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canilicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002;109:1188-91.
40. Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005;41:1117-26.
41. Spell DW, Fadi FF, Lin JT, Jones DV. Epiphora induced by intermittent docetaxel (Taxotere) in patients with non-small cell lung cancer. Cancer Invest 2003;21:550-2.
42. Esmaeli B, Valero V, Ahmadi A, Booser D. Canilicular stenosis secondary to docetaxel (Taxotere). Ophthalmology 2001;108:994-5.
43. Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003;98:504-7.
44. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
45. Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003;80:277-9.
46. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
47. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-65.
48. Maisano R, Mare M, Zavettieri M, et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003;23:1923-6.
49. Anonymous. Anatomical chart series. Hagerstown, MD: Anatomical Chart Company, 1993:19-21.
50. Hurwitz JJ. The lacrimal drainage system. In: Yanoff M, Duker JS, Augsburger JJ, et al, eds. Ophthalmology, 2nd ed. St. Louis: Mosby, Inc; 2004: Available from http://home.mdconsult.com/das/book/body/3780484402/119/133.html. Accessed June 23, 2005.
51. Paul L, Pinto I, Vicente JM, Armendariz A, Moreno G, Baraibar MC. Nasolacrimal stents in the treatment of epiphora: long-term results. J Vasc Interv Radiol 2002;13:83-8.
52. Caesar RH, McNab AA. A brief history of punctoplasty: the 3-snip revisited. Eye 2005;19:16-18.
53. Gridelli C, Gallo C, di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
54. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16:90-6.
55. Kornek GV, Ulrich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-7.
56. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
57. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M. Weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study Anticancer Res 2001;21:1301-6.
58. Estévez LG, Cuevas JM, Antón A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686-92.
59. Dang CT, Andrea GMD, Moynahan ME, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004;10:5754-61.
60. Han JY, Lee DH, Kim HY, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung cancer. Cancer 2003;98:1918-24.
61. Kindwall-Keller T, Otterson GA, Young D, et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005;11:1870-6.
62. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001;92:2158-63.
63. Valerio MR, Russo A, Latteri MA, et al. Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study. Lung Cancer 2001;34(suppl 4):S31-5.
64. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11:1263-6.
65. Dahut WL, Gulley JL, Arien PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
66. Beer TM, Garzotto M, Lowe BA, et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004;10:1306-11.
67. Nadella P, Shapiro C, Otterson GA, et al. Pharmacologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-23.
68. Esmaeli B, Burnstine MA, Ahmadi A, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and nasal mucosa. Ophthal Plast Reconstr Surg 2003;19:305-8.
69. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canilicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002;13:218-21.
70. Jakupeak M. Masculine gender role stress and men's fear of emotions as predictors of self-reported aggression and violence. Violence Vict 2003;18:533-41.
71. Kring AM, Gordon AH. Sex differences in emotion: expression, experience, and physiology J Pers Soc Psychol 1998;74:686-703.
72. Esmaeli B, Ahmadi A, Rivera E, et al. Docetaxel secretion in tears. Arch Opthalmol 2002;120:1180-2.
73. Reilly CH, Kastrup EK, Novak KK, Wickersham RM, Lenzini SW, Weber NR, eds. Drug facts and comparisons 2005. St. Louis: Walters Kluwer Health, 2005:2175.
74. Wenzel C, Locker GJ, Pluschnig U, et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002;50:155-9.
75. Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:1470-3.
76. Ahmadi A, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001;119:1802-4.
77. Baker SD, Zhao M, Lee CKK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004;10:1976-83.
78. Mano MS, Cassidy J, Canney P. Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treat Rev 2005;31:35-48.
79. Harris JR, Morrow M, Norton L. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven Publishers, 1997:1557-602.
80. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
81. Rosing H, Lustig V, van Warmerdam LJ, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-hr intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-18.
82. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 2005;77:43-53.
83. Hainsworth JD, Burris HA, Billings FT, Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma. Cancer 2001;92:2391-8.
84. Hainsworth JD, Burris HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer 2000;89:328-33.
85. Rossi D, Graziano F, Ugolini M, et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study. Tumori 2004;90:50-3.
86. Neubauer MA, Garfield DH, Kuerfler PR, et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 2005;47:121-7.
87. Tsunoda T, Koizumi T, Hayasaka M, et al. Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2004;54:173-7.
88. Niho S, Ohe Y, Kakinuma R, et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 2002;35:209-14.
89. Pectasides D, Visvikis A, Kouloubinis A, et al. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study Eur J Cancer 2002;38:1194-200.
90. Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial. Anticancer Res 2004;24:1211-16.
91. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15:45-50.
92. Ardizzoia A, Acquati M, Fagnani D, et al. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study. Lung 2004;182:1-8.
93. Hainsworth JD, Carrell D, Drengler RL, Scroggin C, Greco FA. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients with poor performance status who have extensive-stage small cell lung carcinoma. Cancer 2004;100:2437-41.
94. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-8.
95. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-9.
96. Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate cancer. Cancer 2003;98:1627-34.
97. Di Lorenzo G, Pizza C, Autorino R, et al. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur Urol 2004;46:712-16.
98. Ferrero JM, Foa C, Thezenas S, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncol 2004;66:281-7.
99. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
100. Petrioli R, Pozzessere D, Messinese S, et al. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncol 2003;64:300-5.
101. Kovács AF, Mose S, Böttcher HD, Bitter K. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 2005;18:26-34.
102. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma: results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys 2004;58:161-6.
103. Varveris H, Delakas D. Anezinis P, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma: a preliminary report of tolerance and local control. Anticancer Res 1997;17:4771-80.
104. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002;13:243-50.
105. Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier oncology group study Oncol 2003;65:218-23.
106. Massacesi C, Marcucci F, Rocchi MBL, Mazzanti P, Pilone A, Bonsignori M. Factors predicting docetaxel-related toxicity: experience at a single institution. J Chemother 2004;16:86-93.
107. Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol 2004;22:2901-8.
108. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriat Med 1997;13:169-83.
109. Ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-7.
110. American Cancer Society. Cancer facts and figures 2005. Available from http://www.cancer.org/downloads/STT/CAFF 2005f4PWSecured.pdf. Accessed June 29, 2005.
111. Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer 1981;48:1539-49.
112. Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg 2003;19:216-24.
113. Sanofi-Synthelabo, Inc. Eloxatin (oxaliplatin injection) package insert. New York, NY; 2005.
114. Supergen, Inc. Nipent (pentostatin for injection) package insert. San Ramon, CA; 1998.
115. Cephalon, Inc. Trisenox (arsenic trioxide injection) package insert. Frazer, PA; 2003.
116. Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983;51:430-2.
117. Pfizer, Inc. Ellence (epirubicin hydrochloride injection) package insert. New York, NY; 2005.
118. Choonara IA, Overend M, Bailey CC. Blurring of vision due to ifosfamide [letter]. Cancer Chemother Pharmacol 1987;20:349.
119. Novak KK, Wickersham RM, Lenzini SW, et al, eds. Drug facts and comparisons 2005. St. Louis: Wolters Kluwer Health; 2005:2282, 2411
120. Sicor Pharmaceuticals, Inc. ThioTEPA for injection, USP package insert. Irvine, CA; 2004.
121. Prasad S, Kamath GG, Phillips PR. Lacrimal canalicular stenosis associated with systemic 5-fluorouracil therapy. Acta Ophthalmol Scand 2000;78:110-13.
122. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy: report of five cases and review of the literature. Doc Opthalmol 1995;90:1-6.
123. Christiphidis N, Lucas I, Vajda FJ, Louis WJ. Lacrimation and 5-fluorouracil [letter], Ann Intern Med 1978;89:574.
124. Hamersley J, Luce JK, Florentz TR, Burkholder MM, Pepper JJ. Excessive lacrimation from fluorouracil treatment. JAMA 1973;225:747-8.
125. Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978;88:657.
126. Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye 1998;12:343-9.
127. Lass JH, Lazarus HM, Reed MD, Herzig RH. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982;94:617-21.
128. Hopen G, Modino BJ, Johnson BL, Chervenice PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91:500-4.
129. Hande KR, Stein RS, McDonough DA, Greco FA, Wolff SN. Effects of high-dose cytarabine. Clin Pharm Ther 1982;31:669-74.
130. Higa GM, Gockerman JP, Hunt AL, Jones MR, Horne BJ. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Cancer 1991;68:1691-3.
131. Cersosimo RJ, Carter RT, Matthews SJ, Coderre M, Karp DD. Acute cerebellar syndrome, conjunctivitis, and hearing loss associated with low-dose cytarabine administration. Drug Intel Clin Pharm 1987;21:798-803.